<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221246</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-002</org_study_id>
    <nct_id>NCT01221246</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours</brief_title>
  <acronym>GMAIS</acronym>
  <official_title>A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genervon Biopharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntington Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarasota Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genervon Biopharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether the investigational drug GM602, is
      effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot
      blocking the flow of blood through one, or more of the blood vessels supplying the brain)
      when administered up to 18 hours after symptoms begin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is a serious and life threatening disease. About 85% of all strokes are ischemic,
      caused by a blood clot or plaque that blocks a blood vessel in the brain. The thrombolytic
      drug tissue plasminogen activator (tPA) is the only early treatment for acute ischemic stroke
      approved by the FDA. Treatment with tPA must be administered within three hours of the stroke
      onset. Furthermore, tPA treatment carries a recognized risk of bleeding in the brain. GM602
      is an investigational drug that may act as a neuroprotectant in patients who have had a
      stroke. It is thought to stop cell death and reduce inflammation in the injured area of the
      brain. This study is designed to evaluate the safety and efficacy of GM602 administered
      intravenously to patients in three consecutive daily doses of 320 mg/dose or 480 mg/dose, the
      initial dose administered within 18 hours after onset of acute ischemic stroke in the Middle
      Cerebral artery region.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2011</start_date>
  <completion_date type="Actual">July 7, 2016</completion_date>
  <primary_completion_date type="Actual">July 7, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint</measure>
    <time_frame>Day 90</time_frame>
    <description>NIH Stroke Scale is a standardized neurological examination intended to describe the neurological deficits found in large groups of stroke patients participating in treatment trials. Percent change from baseline in NIHSS is calculated and compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo</measure>
    <time_frame>Day 30</time_frame>
    <description>Percent change in NIHSS from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo</measure>
    <time_frame>Day 90</time_frame>
    <description>The Barthel Index is measured using both historical and direct observational information. It measures self-care and mobility and will help define the degree of residual disability. Percent change from baseline in BI is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo</measure>
    <time_frame>Day 30</time_frame>
    <description>Percent change in BI from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days</measure>
    <time_frame>Day 90</time_frame>
    <description>compared with placebo at each modified Rankin Scale (mRS) level at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days</measure>
    <time_frame>Day 30</time_frame>
    <description>compared with placebo at each modified Rankin Scale (mRS) level at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo</measure>
    <time_frame>Day 90</time_frame>
    <description>all cause mortality data through 3 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Primary Safety Endpoints</measure>
    <time_frame>througyh 3 months</time_frame>
    <description>Adverse events, Fatal ICH. nonfatal symptomatic parenchymal hemorrhage, or other symptomatic 1CH, Neurological deterioration during hospitalization, Number of seizures after stroke, Respiratory compromise as observed by respiratory rate</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>GM602</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM602</intervention_name>
    <description>First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.</description>
    <arm_group_label>GM602</arm_group_label>
    <other_name>GM6</other_name>
    <other_name>GM604</other_name>
    <other_name>GM608</other_name>
    <other_name>MNTF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>Bacteriostatic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  Be eligible for MRI or CT scan

          -  Have suffered acute ischemic stroke in the middle cerebral artery (MCA) distribution,
             as verified by the Screening DWI abnormality and Screening PWI abnormality

          -  Have NIH Stroke Scale (NIHSS) score total score of 9-20 inclusive at screening

          -  Have suffered acute ischemic stroke within 18 hours

          -  Have been functionally independent with a Modified Rankin Score (mRS) of 0 or 1 prior
             to suffering stroke

          -  Patients who received tPA or FDA approved mechanical device can also enroll

          -  completed informed consent form

        Exclusion Criteria:

          -  Have history of stroke in the past 3 months

          -  Cannot be evaluated using MRI/CT

          -  Have stroke of the brainstem or cerebellum

          -  Have clinical presentation consistent with acute MI by EKG criteria (STEMI) at
             screening

          -  Have hemorrhage revealed by CT or MRI scan

          -  Have &gt; 1/3 MCA territory HYPER intensity as seen on MRI OR &gt;1/3 MCA territory HYPO
             intensity as seen on CT

          -  Have blood sugar level &gt;400 mg/DL or&lt;50 mg/dL

          -  Have kidney disease, creatinine &gt; 2.0

          -  Have had recent (within 90 days) serious head trauma or head trauma with loss of
             consciousness

          -  Have any prior history of seizure

          -  Have clinically relevant pre-existing neurological deficit (Historical Rankin score â‰¥
             2)

          -  Have any other known clinically significant medical disorder (cardiovascular, hepatic,
             renal, endocrine, respiratory, immunological, cancer, AIDS)

          -  Life expectancy of less than 6 months due to comorbid conditions

          -  Women of child bearing potential who are pregnant or breast-feeding or unable to
             practice birth control during the study period

          -  Have participated in any other trial of an investigational agent within 90 days prior
             to screening

          -  Informed consent cannot be obtained

          -  Unable to participate in study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arbi G Ohanian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntington Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sidney Starkman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Stroke Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Saver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Stroke Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoag Memorial Hospital Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan A Mayer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nobl Barazangi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas G Devlin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Erlanger Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauricio Concha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarasota Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anand Vaishnav, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Memorial Hospital Stroke Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Erlanger Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Middle Cerebral Artery Ischemic Stroke within 18 hours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

